Corporate Profile

Ovid Therapeutics is a New York-based biopharmaceutical company striving to conquer epilepsies and seizures with courageous science. Ovid is developing a pipeline of potential small molecule medicines that seek to meaningfully improve the lives of those affected by rare epilepsies and disorders with seizure symptoms. Ovid’s team has three clinical-stage programs and one preclinical platform to-date. This pipeline of programs includes:

OV329, a next-generation GABA aminotransferase inhibitor for refractory seizures, which is currently in a Phase 1 study. OV329 is a more potent GABA-AT inhibitor, and as a result, Ovid believes it may confer seizure reduction efficacy and preferred safety and dosing relative to prior medicines in the class.

Ovid recently in-licensed two other platforms for development, including highly selective ROCK2 inhibitors (in collaboration with Graviton Biosciences) and KCC2 direct activators. The mechanisms of action that Ovid pursues for investigational medicines are designed to intercept novel or under- addressed biological targets that are believed to directly or indirectly cause seizures. These potential first-in-class or best-in-class compounds are designed to potentially reduce seizures and deliver preferable tolerability and safety; making them easier to incorporate into treatment plans.

In addition, Ovid retains financial rights to soticlestat, a novel inhibitor of cholesterol 24 hydroxylase. Ovid co-developed and out-licensed its rights to soticlestat to Takeda. Soticlestat is currently being studied by Takeda in two, pivotal Phase 3 trials for Dravet syndrome and Lennox-Gastaut syndrome and is projected for regulatory approval submissions in Takeda’s fiscal year 2024.

Ovid is led by a veteran team whose collective experience has contributed to the development and commercialization of more than 25 medicines for neurological and rare diseases in the last two decades.

Corporate Presentation

Upcoming & Recent Events

View All Events

Recent News

View all news

quarterly reports & investor resources